The DOI matches its Crossref record; 435 of the 435 references it cites were found in a registry or an index.
Modulating ROS to overcome multidrug resistance in cancer
Abstract
The successful treatment of cancer has significantly improved as a result of targeted therapy and immunotherapy. However, during chemotherapy, cancer cells evolve and can acquire "multidrug resistance" (MDR), which significantly limits the efficacy of cancer treatment and impacts patient survival and quality of life. Among the approaches to reverse MDR, modulating reactive oxidative species (ROS) may represent a strategy to kill MDR cancer cells that are mechanistically diverse. ROS in cancer cells play a central role in regulating and inducing apoptosis, thereby modulating cancer cells proliferation, survival and drug resistance. The levels of ROS and the activity of scavenging/anti-oxidant enzymes in drug resistant cancer cells are typically increased compared to non-MDR cancer and normal cells. Consequently, MDR cancer cells may be more susceptible to alterations in ROS levels. Numerous studies suggest that compounds modulating cellular ROS levels can enhance MDR cancer cell death and sensitize MDR cancer cells to certain chemotherapeutic drugs. In the current review, we discuss the critical and targetable redox-regulating enzymes, including mitochondrial electron transport chain (ETC) complexes, NADPH oxidases (NOXs), enzymes related to glutathione metabolism, glutamate/cystine antiporter xCT, thioredoxin reductases (TrxRs), nuclear factor erythroid 2-related factor 2 (Nrf2), and their roles in regulating cellular ROS levels, drug resistance as well as their clinical significance. We also discuss and summarize the findings in the past decade regarding the efficacy of ROS modulators for the treatment of MDR cancer alone or as sensitizing compounds. Compounds that are efficacious in modulating ROS generation represent a prominent class of drug candidates that warrants evaluation in clinical trials for patients harboring MDR cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
4 retracted
Targeted production of reactive oxygen species in mitochondria to overcome cancer drug resistance
Wang, H., Gao, Z., Liu, X., Agarwal, P., Zhao, S., Conroy, D. W., Ji, G., Yu, J., Jaroniec, C. P., Liu, Z., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-02915-8 · Cited by 331
RetractedCHEN, L., LI, X., LIU, L., YU, B., XUE, Y., & LIU, Y. (2015) · Oncology Reports · doi:10.3892/or.2015.3712 · Cited by 279
RetractedXu, X., Zhang, X., Zhang, Y., Yang, L., Liu, Y., Huang, S., Lu, L., Kong, L., Li, Z., Guo, Q., et al. (2017) · Scientific Reports · doi:10.1038/srep39950 · Cited by 42
RetractedCollateral Sensitivity of Multidrug-Resistant Cells to the Orphan Drug Tiopronin
Goldsborough, A. S., Handley, M. D., Dulcey, A. E., Pluchino, K. M., Kannan, P., Brimacombe, K. R., Hall, M. D., Griffiths, G. L., & Gottesman, M. M. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm2001663 · Cited by 36
RetractedFerroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death
Dixon, S. J., Lemberg, K. M., Lamprecht, M. R., Skouta, R., Zaitsev, E. M., Gleason, C. E., Patel, D. N., Bauer, A. J., Cantley, A. M., Yang, W. S., et al. (2012) · Cell · doi:10.1016/j.cell.2012.03.042 · Cited by 18,691
How mitochondria produce reactive oxygen species
Murphy, M. P. (2009) · Biochemical Journal · doi:10.1042/bj20081386 · Cited by 8,207
ROS function in redox signaling and oxidative stress
Schieber, M., & Chandel, N. S. (2014) · Current Biology · doi:10.1016/j.cub.2014.03.034 · Cited by 6,931
Ayala, A., Muñoz, M. F., & Argüelles, S. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/360438 · Cited by 6,349
Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
Oxidative Stress and Antioxidant Defense
Birben, E., Sahiner, U. M., Sackesen, C., Erzurum, S., & Kalayci, O. (2012) · World Allergy Organization Journal · doi:10.1097/wox.0b013e3182439613 · Cited by 4,935
Reactive oxygen species (ROS) homeostasis and redox regulation in cellular signaling
Ray, P. D., Huang, B.-W., & Tsuji, Y. (2012) · Cellular Signalling · doi:10.1016/j.cellsig.2012.01.008 · Cited by 4,373
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
Kobayashi, S., Boggon, T. J., Dayaram, T., Jänne, P. A., Kocher, O., Meyerson, M., Johnson, B. E., Eck, M. J., Tenen, D. G., & Halmos, B. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044238 · Cited by 3,964
Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., & Gianni, L. (2004) · Pharmacological Reviews · doi:10.1124/pr.56.2.6 · Cited by 3,778
Crosstalk of reactive oxygen species and NF-κB signaling
Morgan, M. J., & Liu, Z.-G. (2011) · Cell Research · doi:10.1038/cr.2010.178 · Cited by 3,505
Reactive oxygen species in cancer
Liou, G.-Y., & Storz, P. (2010) · Free Radical Research · doi:10.3109/10715761003667554 · Cited by 3,382
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296
Advances in metal-induced oxidative stress and human disease
Jomova, K., & Valko, M. (2011) · Toxicology · doi:10.1016/j.tox.2011.03.001 · Cited by 3,207
Drug resistance in cancer: An overview
Housman, G., Byler, S., Heerboth, S., Lapinska, K., Longacre, M., Snyder, N., & Sarkar, S. (2014) · Cancers · doi:10.3390/cancers6031769 · Cited by 2,463
Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening
Gupta, P. B., Onder, T. T., Jiang, G., Tao, K., Kuperwasser, C., Weinberg, R. A., & Lander, E. S. (2009) · Cell · doi:10.1016/j.cell.2009.06.034 · Cited by 2,389
Self-citationHematologic and Cytogenetic Responses to Imatinib Mesylate in Chronic Myelogenous Leukemia
Kantarjian, H., Sawyers, C., Hochhaus, A., Guilhot, F., Schiffer, C., Gambacorti-Passerini, C., Niederwieser, D., Resta, D., Capdeville, R., Zoellner, U., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa011573 · Cited by 2,019
Sun, X., Ou, Z., Chen, R., Niu, X., Chen, D., Kang, R., & Tang, D. (2016) · Hepatology · doi:10.1002/hep.28251 · Cited by 2,012
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway
Viswanathan, V. S., Ryan, M. J., Dhruv, H. D., Gill, S., Eichhoff, O. M., Seashore-Ludlow, B., Kaffenberger, S. D., Eaton, J. K., Shimada, K., Aguirre, A. J., et al. (2017) · Nature · doi:10.1038/nature23007 · Cited by 2,011
Ros and ros-mediated cellular signaling
Zhang, J., Wang, X., Vikash, V., Ye, Q., Wu, D., Liu, Y., & Dong, W. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/4350965 · Cited by 1,980
A History of Cancer Chemotherapy
DeVita, V. T., & Chu, E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6611 · Cited by 1,970
Free radical-mediated oxidation of free amino acids and amino acid residues in proteins
Stadtman, E. R., & Levine, R. L. (2003) · Amino Acids · doi:10.1007/s00726-003-0011-2 · Cited by 1,962
Revisiting the role of ABC transporters in multidrug-resistant cancer
Robey, R. W., Pluchino, K. M., Hall, M. D., Fojo, A. T., Bates, S. E., & Gottesman, M. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0005-8 · Cited by 1,866
Lipid peroxidation in cell death
Gaschler, M. M., & Stockwell, B. R. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.10.086 · Cited by 1,828
Farber, S., Diamond, L. K., Mercer, R. D., Sylvester, R. F., & Wolff, J. A. (1948) · New England Journal of Medicine · doi:10.1056/nejm194806032382301 · Cited by 1,806
Targeting DNA topoisomerase II in cancer chemotherapy
Nitiss, J. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2607 · Cited by 1,791
Mitchell, J. A., Akarasereenont, P., Thiemermann, C., Flower, R. J., & Vane, J. R. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.24.11693 · Cited by 1,659
Update of the LIPID MAPS comprehensive classification system for lipids
Fahy, E., Subramaniam, S., Murphy, R. C., Nishijima, M., Raetz, C. R. H., Shimizu, T., Spener, F., van Meer, G., Wakelam, M. J. O., & Dennis, E. A. (2009) · Journal of Lipid Research · doi:10.1194/jlr.r800095-jlr200 · Cited by 1,628
Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel?
Sabharwal, S. S., & Schumacker, P. T. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3803 · Cited by 1,622
Thress, K. S., Paweletz, C. P., Felip, E., Cho, B. C., Stetson, D., Dougherty, B., Lai, Z., Markovets, A., Vivancos, A., Kuang, Y., et al. (2015) · Nature Medicine · doi:10.1038/nm.3854 · Cited by 1,589
Topology of superoxide production from different sites in the mitochondrial electron transport chain
St-Pierre, J., Buckingham, J. A., Roebuck, S. J., & Brand, M. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m207217200 · Cited by 1,545
Nita, M., & Grzybowski, A. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/3164734 · Cited by 1,448
Li, N., Ragheb, K., Lawler, G., Sturgis, J., Rajwa, B., Melendez, J. A., & Robinson, J. P. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m210432200 · Cited by 1,433
Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug
Capdeville, R., Buchdunger, E., Zimmermann, J., & Matter, A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd839 · Cited by 1,389
Targeting mitochondria metabolism for cancer therapy
Weinberg, S. E., & Chandel, N. S. (2015) · Nature Chemical Biology · doi:10.1038/nchembio.1712 · Cited by 1,381
The changing faces of glutathione, a cellular protagonist
Pompella, A., Visvikis, A., Paolicchi, A., Tata, V. D., & Casini, A. F. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00504-5 · Cited by 1,359
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337
The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer
Kansanen, E., Kuosmanen, S. M., Leinonen, H., & Levonen, A.-L. (2013) · Redox Biology · doi:10.1016/j.redox.2012.10.001 · Cited by 1,313
The emerging role of the Nrf2–Keap1 signaling pathway in cancer
Jaramillo, M. C., & Zhang, D. D. (2013) · Genes & Development · doi:10.1101/gad.225680.113 · Cited by 1,297
Lubos, E., Loscalzo, J., & Handy, D. E. (2011) · Antioxidants & Redox Signaling · doi:10.1089/ars.2010.3586 · Cited by 1,280
Mitochondrial metabolism and cancer
Porporato, P. E., Filigheddu, N., Pedro, J. M. B.-S., Kroemer, G., & Galluzzi, L. (2018) · Cell Research · doi:10.1038/cr.2017.155 · Cited by 1,273
Kinase-targeted cancer therapies: progress, challenges and future directions
Bhullar, K. S., Lagarón, N. O., McGowan, E. M., Parmar, I., Jha, A., Hubbard, B. P., & Rupasinghe, H. P. V. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0804-2 · Cited by 1,245
Glutathione metabolism in cancer progression and treatment resistance
Bansal, A., & Simon, M. C. (2018) · Journal of Cell Biology · doi:10.1083/jcb.201804161 · Cited by 1,233
Mitogen-Activated Protein Kinases and Reactive Oxygen Species: How Can ROS Activate MAPK Pathways?
Son, Y., Cheong, Y.-K., Kim, N.-H., Chung, H.-T., Kang, D. G., & Pae, H.-O. (2011) · Journal of Signal Transduction · doi:10.1155/2011/792639 · Cited by 1,219
Ishimoto, T., Nagano, O., Yae, T., Tamada, M., Motohara, T., Oshima, H., Oshima, M., Ikeda, T., Asaba, R., Yagi, H., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.01.038 · Cited by 1,192
(2002) · PubMed · Cited by 1,190
Analysis of glutathione: implication in redox and detoxification
Pastore, A., Federici, G., Bertini, E., & Piemonte, F. (2003) · Clinica Chimica Acta · doi:10.1016/s0009-8981(03)00200-6 · Cited by 1,186
Sawyers, C. L. (2002) · Blood · doi:10.1182/blood.v99.10.3530 · Cited by 1,146
Distribution and biological activities of the flavonoid luteolin
Lopez-Lazaro, M. (2009) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/138955709787001712 · Cited by 1,106
Trachootham, D., Zhou, Y., Zhang, H., Demizu, Y., Chen, Z., Pelicano, H., Chiao, P. J., Achanta, G., Arlinghaus, R. B., Liu, J., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.08.009 · Cited by 1,080
The emerging role of Nrf2 in mitochondrial function
Dinkova-Kostova, A. T., & Abramov, A. Y. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.04.036 · Cited by 983
The role of reactive oxygen and antioxidant species in periodontal tissue destruction
Chapple, I. L. C., & Matthews, J. B. (2007) · Periodontology 2000 · doi:10.1111/j.1600-0757.2006.00178.x · Cited by 936
An inhibitor of oxidative phosphorylation exploits cancer vulnerability
Molina, J. R., Sun, Y., Protopopova, M., Gera, S., Bandi, M., Bristow, C., McAfoos, T., Morlacchi, P., Ackroyd, J., Agip, A.-N. A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0052-4 · Cited by 928
DNA Base Damage by Reactive Oxygen Species, Oxidizing Agents, and UV Radiation
Cadet, J., & Wagner, J. R. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a012559 · Cited by 903
Molecular mechanisms of ROS production and oxidative stress in diabetes
Newsholme, P., Cruzat, V. F., Keane, K. N., Carlessi, R., & de Bittencourt, P. I. H. (2016) · Biochemical Journal · doi:10.1042/bcj20160503c · Cited by 878
Nrf2 enhances resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2
Wang, X.-J., Sun, Z., Villeneuve, N. F., Zhang, S., Zhao, F., Li, Y., Chen, W., Yi, X., Zheng, W., Wondrak, G. T., et al. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn095 · Cited by 839
Mitochondrial proton and electron leaks
Jastroch, M., Divakaruni, A. S., Mookerjee, S., Treberg, J. R., & Brand, M. D. (2010) · Essays in Biochemistry · doi:10.1042/bse0470053 · Cited by 829
Oxidative Stress and Lipid Peroxidation Products in Cancer Progression and Therapy
Barrera, G. (2012) · ISRN Oncology · doi:10.5402/2012/137289 · Cited by 820
Reactive Oxygen Species: A Key Constituent in Cancer Survival
Kumari, S., Badana, A. K., G, M. M., G, S., & Malla, R. (2018) · Biomarker Insights · doi:10.1177/1177271918755391 · Cited by 777
ROS-Mediated Lipid Peroxidation and RES-Activated Signaling
Farmer, E. E., & Mueller, M. J. (2013) · Annual Review of Plant Biology · doi:10.1146/annurev-arplant-050312-120132 · Cited by 756
Boonstra, J., & Post, J. A. (2004) · Gene · doi:10.1016/j.gene.2004.04.032 · Cited by 737
Gupta, S. C., Hevia, D., Patchva, S., Park, B., Koh, W., & Aggarwal, B. B. (2012) · Antioxidants & Redox Signaling · doi:10.1089/ars.2011.4414 · Cited by 732
Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis
Fan, Z., Wirth, A.-K., Chen, D., Wruck, C. J., Rauh, M., Buchfelder, M., & Savaskan, N. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.65 · Cited by 692
Focus on mammalian thioredoxin reductases — Important selenoproteins with versatile functions
Arnér, E. S. J. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.01.014 · Cited by 673
L??scher, W. (2002) · CNS Drugs · doi:10.2165/00023210-200216100-00003 · Cited by 664
ZITKA, O., SKALICKOVA, S., GUMULEC, J., MASARIK, M., ADAM, V., HUBALEK, J., TRNKOVA, L., KRUSEOVA, J., ECKSCHLAGER, T., & KIZEK, R. (2012) · Oncology Letters · doi:10.3892/ol.2012.931 · Cited by 664
Cucurbitacins and cucurbitane glycosides: structures and biological activities
Chen, J. C., Chiu, M. H., Nie, R. L., Cordell, G. A., & Qiu, S. X. (2005) · Natural Product Reports · doi:10.1039/b418841c · Cited by 635
Loss of Keap1 Function Activates Nrf2 and Provides Advantages for Lung Cancer Cell Growth
Ohta, T., Iijima, K., Miyamoto, M., Nakahara, I., Tanaka, H., Ohtsuji, M., Suzuki, T., Kobayashi, A., Yokota, J., Sakiyama, T., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-5003 · Cited by 629
Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer
Parker, W. B. (2009) · Chemical Reviews · doi:10.1021/cr900028p · Cited by 622
Singh, A., Venkannagari, S., Oh, K. H., Zhang, Y.-Q., Rohde, J. M., Liu, L., Nimmagadda, S., Sudini, K., Brimacombe, K. R., Gajghate, S., et al. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00651 · Cited by 617
Mitochondrial ATP synthase: architecture, function and pathology
Jonckheere, A. I., Smeitink, J. A. M., & Rodenburg, R. J. T. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-011-9382-9 · Cited by 605
MUSTACICH, D., & POWIS, G. (2000) · Biochemical Journal · doi:10.1042/bj3460001 · Cited by 592
The thioredoxin system in cancer
Arnér, E. S. J., & Holmgren, A. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.10.009 · Cited by 589
Role of Reactive Oxygen Species (ROS) in Therapeutics and Drug Resistance in Cancer and Bacteria
Dharmaraja, A. T. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01243 · Cited by 582
Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
Lipson, E. J., & Drake, C. G. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1595 · Cited by 570
Pancreatic cancer: from state-of-the-art treatments to promising novel therapies
Garrido-Laguna, I., & Hidalgo, M. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.53 · Cited by 565
Basit, F., van Oppen, L. M., Schöckel, L., Bossenbroek, H. M., van Emst-de Vries, S. E., Hermeling, J. C., Grefte, S., Kopitz, C., Heroult, M., HGM Willems, P., et al. (2017) · Cell Death & Disease · doi:10.1038/cddis.2017.133 · Cited by 565
Nrf2 Protein Up-regulates Antiapoptotic Protein Bcl-2 and Prevents Cellular Apoptosis
Niture, S. K., & Jaiswal, A. K. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.312694 · Cited by 545
Cramer, S. L., Saha, A., Liu, J., Tadi, S., Tiziani, S., Yan, W., Triplett, K., Lamb, C., Alters, S. E., Rowlinson, S., et al. (2017) · Nature Medicine · doi:10.1038/nm.4232 · Cited by 538
Auranofin: Repurposing an Old Drug for a Golden New Age
Roder, C., & Thomson, M. J. (2015) · Drugs in R&D · doi:10.1007/s40268-015-0083-y · Cited by 497
Lysosomes as mediators of drug resistance in cancer
Zhitomirsky, B., & Assaraf, Y. G. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2015.11.004 · Cited by 482
Self-citationYu, Y., Xie, Y., Cao, L., Yang, L., Yang, M., Lotze, M. T., Zeh, H. J., Kang, R., & Tang, D. (2015) · Molecular & Cellular Oncology · doi:10.1080/23723556.2015.1054549 · Cited by 468
Targeting the Thioredoxin System for Cancer Therapy
Zhang, J., Li, X., Han, X., Liu, R., & Fang, J. (2017) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.06.001 · Cited by 460
Antifolates in cancer therapy: Structure, activity and mechanisms of drug resistance
Gonen, N., & Assaraf, Y. G. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.07.002 · Cited by 437
Self-citationKawanishi, S., Hiraku, Y., & Oikawa, S. (2001) · Mutation Research/Reviews in Mutation Research · doi:10.1016/s1383-5742(00)00059-4 · Cited by 433
The Pharmacologic and Clinical Effects of Medical Cannabis
Borgelt, L. M., Franson, K. L., Nussbaum, A. M., & Wang, G. S. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1187 · Cited by 423
Nrf2 Enhances Cell Proliferation and Resistance to Anticancer Drugs in Human Lung Cancer
Homma, S., Ishii, Y., Morishima, Y., Yamadori, T., Matsuno, Y., Haraguchi, N., Kikuchi, N., Satoh, H., Sakamoto, T., Hizawa, N., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2822 · Cited by 418
Laborde, E. (2010) · Cell Death & Differentiation · doi:10.1038/cdd.2010.80 · Cited by 409
Lehmann, S., Bykov, V. J. N., Ali, D., Andrén, O., Cherif, H., Tidefelt, U., Uggla, B., Yachnin, J., Juliusson, G., Moshfegh, A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.7783 · Cited by 406
Sato, M., Kusumi, R., Hamashima, S., Kobayashi, S., Sasaki, S., Komiyama, Y., Izumikawa, T., Conrad, M., Bannai, S., & Sato, H. (2018) · Scientific Reports · doi:10.1038/s41598-018-19213-4 · Cited by 403
O'Day, S. J., Eggermont, A. M. M., Chiarion-Sileni, V., Kefford, R., Grob, J. J., Mortier, L., Robert, C., Schachter, J., Testori, A., Mackiewicz, J., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.5585 · Cited by 373
Mechanisms of Chemoresistance to Alkylating Agents in Malignant Glioma
Sarkaria, J. N., Kitange, G. J., James, C. D., Plummer, R., Calvert, H., Weller, M., & Wick, W. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1719 · Cited by 373
Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer
Roh, J.-L., Kim, E. H., Jang, H. J., Park, J. Y., & Shin, D. (2016) · Cancer Letters · doi:10.1016/j.canlet.2016.07.035 · Cited by 373
The cell cycle is a redox cycle: Linking phase-specific targets to cell fate
Burhans, W. C., & Heintz, N. H. (2009) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2009.05.026 · Cited by 361
Targeting Breast Cancer Stem Cell State Equilibrium through Modulation of Redox Signaling
Luo, M., Shang, L., Brooks, M. D., Jiagge, E., Zhu, Y., Buschhaus, J. M., Conley, S., Fath, M. A., Davis, A., Gheordunescu, E., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.06.006 · Cited by 358
Nagai, M., Vo, N. H., Shin Ogawa, L., Chimmanamada, D., Inoue, T., Chu, J., Beaudette-Zlatanova, B. C., Lu, R., Blackman, R. K., Barsoum, J., et al. (2012) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2012.03.017 · Cited by 357
Strategies for reversing drug resistance
Fojo, T., & Bates, S. (2003) · Oncogene · doi:10.1038/sj.onc.1206951 · Cited by 357
Marlein, C. R., Zaitseva, L., Piddock, R. E., Robinson, S. D., Edwards, D. R., Shafat, M. S., Zhou, Z., Lawes, M., Bowles, K. M., & Rushworth, S. A. (2017) · Blood · doi:10.1182/blood-2017-03-772939 · Cited by 354
Elesclomol induces cancer cell apoptosis through oxidative stress
Kirshner, J. R., He, S., Balasubramanyam, V., Kepros, J., Yang, C.-Y., Zhang, M., Du, Z., Barsoum, J., & Bertin, J. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0298 · Cited by 353
DNA damage by reactive species: Mechanisms, mutation and repair
Jena, N. R. (2012) · Journal of Biosciences · doi:10.1007/s12038-012-9218-2 · Cited by 344
Toward a Better Understanding of the Complexity of Cancer Drug Resistance
Gottesman, M. M., Lavi, O., Hall, M. D., & Gillet, J.-P. (2016) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010715-103111 · Cited by 327
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential
Wang, L., Leite de Oliveira, R., Huijberts, S., Bosdriesz, E., Pencheva, N., Brunen, D., Bosma, A., Song, J.-Y., Zevenhoven, J., Los-de Vries, G. T., et al. (2018) · Cell · doi:10.1016/j.cell.2018.04.012 · Cited by 327
Tang, X., Wang, H., Fan, L., Wu, X., Xin, A., Ren, H., & Wang, X. J. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.03.008 · Cited by 325
Hu, Y. J., & Diamond, A. M. (2003) · PubMed · Cited by 314
Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance
Bar-Zeev, M., Livney, Y. D., & Assaraf, Y. G. (2017) · Drug Resistance Updates · doi:10.1016/j.drup.2017.05.002 · Cited by 314
Self-citationCollateral sensitivity as a strategy against cancer multidrug resistance
Pluchino, K. M., Hall, M. D., Goldsborough, A. S., Callaghan, R., & Gottesman, M. M. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.03.002 · Cited by 305
Glabrene and isoliquiritigenin as tyrosinase inhibitors from licorice roots
Nerya, O., Vaya, J., Musa, R., Izrael, S., Ben-Arie, R., & Tamir, S. (2003) · Journal of Agricultural and Food Chemistry · doi:10.1021/jf020935u · Cited by 297
The Nrf2/HO‐1 Axis in Cancer Cell Growth and Chemoresistance
Furfaro, A. L., Traverso, N., Domenicotti, C., Piras, S., Moretta, L., Marinari, U. M., Pronzato, M. A., & Nitti, M. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/1958174 · Cited by 295
Kantarjian, H. M., Cortes, J., O'Brien, S., Giles, F. J., Albitar, M., Rios, M. B., Shan, J., Faderl, S., Garcia-Manero, G., Thomas, D. A., et al. (2002) · Blood · doi:10.1182/blood.v99.10.3547 · Cited by 295
Celastrol: Molecular targets of Thunder God Vine
Salminen, A., Lehtonen, M., Paimela, T., & Kaarniranta, K. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2010.03.050 · Cited by 293
N-acetylcysteine, reactive oxygen species and beyond
Sun, S.-Y. (2010) · Cancer Biology & Therapy · doi:10.4161/cbt.9.2.10583 · Cited by 288
Role of Glutathione in the Regulation of Cisplatin Resistance in Cancer Chemotherapy
Chen, H. H. W., & Kuo, M. T. (2010) · Metal-Based Drugs · doi:10.1155/2010/430939 · Cited by 287
MnSOD in Oxidative Stress Response-Potential Regulation via Mitochondrial Protein Influx
Candas, D., & Li, J. J. (2014) · Antioxidants & Redox Signaling · doi:10.1089/ars.2013.5305 · Cited by 286
Lee, S.-R., Bar-Noy, S., Kwon, J., Levine, R. L., Stadtman, T. C., & Rhee, S. G. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.050579797 · Cited by 269
Lissanu Deribe, Y., Sun, Y., Terranova, C., Khan, F., Martinez-Ledesma, J., Gay, J., Gao, G., Mullinax, R. A., Khor, T., Feng, N., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0019-5 · Cited by 268
Self-citationPolyamine catabolism and oxidative damage
Murray Stewart, T., Dunston, T. T., Woster, P. M., & Casero, R. A. (2018) · Journal of Biological Chemistry · doi:10.1074/jbc.tm118.003337 · Cited by 268
Valproate in the treatment of epilepsy in girls and women of childbearing potential
Tomson, T., Marson, A., Boon, P., Canevini, M. P., Covanis, A., Gaily, E., Kälviäinen, R., & Trinka, E. (2015) · Epilepsia · doi:10.1111/epi.13021 · Cited by 267
Cancer, Oxidative Stress, and Metastasis
Gill, J. G., Piskounova, E., & Morrison, S. J. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030791 · Cited by 266
Taylor, S., Spugnini, E. P., Assaraf, Y. G., Azzarito, T., Rauch, C., & Fais, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.08.004 · Cited by 259
Self-citationKühn, H., & Borchert, A. (2002) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(02)00855-9 · Cited by 253
Drug resistance in pancreatic cancer: Impact of altered energy metabolism
Grasso, C., Jansen, G., & Giovannetti, E. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.03.026 · Cited by 253
Biochemical dysfunction in heart mitochondria exposed to ischaemia and reperfusion
Solaini, G., & Harris, D. A. (2005) · Biochemical Journal · doi:10.1042/bj20042006 · Cited by 252
Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer
Lien, E. C., Lyssiotis, C. A., Juvekar, A., Hu, H., Asara, J. M., Cantley, L. C., & Toker, A. (2016) · Nature Cell Biology · doi:10.1038/ncb3341 · Cited by 249
Reactive oxygen species-mediated therapeutic response and resistance in glioblastoma
Singer, E., Judkins, J., Salomonis, N., Matlaf, L., Soteropoulos, P., McAllister, S., & Soroceanu, L. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.566 · Cited by 249
Different strategies to overcome multidrug resistance in cancer
Saraswathy, M., & Gong, S. (2013) · Biotechnology Advances · doi:10.1016/j.biotechadv.2013.06.004 · Cited by 248
Singh, A., Rangasamy, T., Thimmulappa, R. K., Lee, H., Osburn, W. O., Brigelius-Flohé, R., Kensler, T. W., Yamamoto, M., & Biswal, S. (2006) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2005-0325oc · Cited by 248
Glutathione peroxidase 4 prevents necroptosis in mouse erythroid precursors
Canli, Ö., Alankuş, Y. B., Grootjans, S., Vegi, N., Hültner, L., Hoppe, P. S., Schroeder, T., Vandenabeele, P., Bornkamm, G. W., & Greten, F. R. (2016) · Blood · doi:10.1182/blood-2015-06-654194 · Cited by 247
Kwiecień, S., Jasnos, K., Magierowski, M., Śliwowski, Z., Pajdo, R., Brzozowski, B., Mach, T., Wójcik-Grzybek, D., & Brzozowski, T. (2014) · PubMed · Cited by 247
Glutathione synthesis and its role in redox signaling
Zhang, H., & Forman, H. J. (2012) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2012.03.017 · Cited by 245
The influence of reactive oxygen species on cell cycle progression in mammalian cells
Verbon, E. H., Post, J. A., & Boonstra, J. (2012) · Gene · doi:10.1016/j.gene.2012.08.038 · Cited by 233
Yu, Y. P., Yu, G., Tseng, G., Cieply, K., Nelson, J., Defrances, M., Zarnegar, R., Michalopoulos, G., & Luo, J.-H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0648 · Cited by 231
Mitochondrial Respiratory Chain Complexes
Sousa, J. S., D’Imprima, E., & Vonck, J. (2018) · Subcellular Biochemistry · doi:10.1007/978-981-10-7757-9_7 · Cited by 231
Mitochondrial Dysfunction Indirectly Elevates ROS Production by the Endoplasmic Reticulum
Murphy, M. P. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.07.006 · Cited by 230
Role of Oxidative Stress in Stem, Cancer, and Cancer Stem Cells
Dayem, A. A., Choi, H.-Y., Kim, J.-H., & Cho, S.-G. (2010) · Cancers · doi:10.3390/cancers2020859 · Cited by 229
Reactive oxygen species at phospholipid bilayers: Distribution, mobility and permeation
Cordeiro, R. M. (2014) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2013.09.016 · Cited by 228
Jiang, J., Wang, K., Chen, Y., Chen, H., Nice, E. C., & Huang, C. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.36 · Cited by 228
Roles of Nrf2 in cell proliferation and differentiation
Murakami, S., & Motohashi, H. (2015) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2015.06.030 · Cited by 225
Petrosillo, G., Ruggiero, F. M., Pistolese, M., & Paradies, G. (2001) · FEBS Letters · doi:10.1016/s0014-5793(01)03206-9 · Cited by 224
Drayton, R. M., Dudziec, E., Peter, S., Bertz, S., Hartmann, A., Bryant, H. E., & Catto, J. W. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2805 · Cited by 220
Mechanisms of ROS modulated cell survival during carcinogenesis
Clerkin, J. S., Naughton, R., Quiney, C., & Cotter, T. G. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.02.029 · Cited by 219
Nrf2: control of sensitivity to carcinogens
Slocum, S. L., & Kensler, T. W. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0675-4 · Cited by 219
McWalter, G. K., Higgins, L. G., McLellan, L. I., Henderson, C. J., Hayes, J. D., Song, L., Thornalley, P. J., Itoh, K., & Yamamoto, M. (2004) · The Journal of Nutrition · doi:10.1093/jn/134.12.3499s · Cited by 216
The multifaceted role of glutathione S-transferases in cancer
Chatterjee, A., & Gupta, S. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.06.028 · Cited by 215
FARBER, S. (1949) · Blood · doi:10.1182/blood.v4.2.160.160 · Cited by 209
O'Day, S., Gonzalez, R., Lawson, D., Weber, R., Hutchins, L., Anderson, C., Haddad, J., Kong, S., Williams, A., & Jacobson, E. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.1579 · Cited by 208
DNA Damage and Repair: Relevance to Mechanisms of Neurodegeneration
Martin, L. J. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31816ff780 · Cited by 207
Rationally designed nanovehicles to overcome cancer chemoresistance
Livney, Y. D., & Assaraf, Y. G. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.08.006 · Cited by 205
Self-citationLipids in cell biology: how can we understand them better?
Muro, E., Atilla-Gokcumen, G. E., & Eggert, U. S. (2014) · Molecular Biology of the Cell · doi:10.1091/mbc.e13-09-0516 · Cited by 205
Shanmugasundaram, K., Nayak, B. K., Friedrichs, W. E., Kaushik, D., Rodriguez, R., & Block, K. (2017) · Nature Communications · doi:10.1038/s41467-017-01106-1 · Cited by 204
The role of peroxiredoxins in cancer
Nicolussi, A., D'Inzeo, S., Capalbo, C., Giannini, G., & Coppa, A. (2017) · Molecular and Clinical Oncology · doi:10.3892/mco.2017.1129 · Cited by 200
Intraperoxisomal redox balance in mammalian cells: oxidative stress and interorganellar cross-talk
Ivashchenko, O., Van Veldhoven, P. P., Brees, C., Ho, Y.-S., Terlecky, S. R., & Fransen, M. (2011) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-11-0919 · Cited by 199
Brewer, T. F., Garcia, F. J., Onak, C. S., Carroll, K. S., & Chang, C. J. (2015) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-060614-034018 · Cited by 198
DNA–Protein Cross-Links: Formation, Structural Identities, and Biological Outcomes
Tretyakova, N. Y., Groehler, A., & Ji, S. (2015) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5b00056 · Cited by 197
The role of glutathione in brain tumor drug resistance
Backos, D. S., Franklin, C. C., & Reigan, P. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.11.016 · Cited by 196
Gao, A.-M., Ke, Z.-P., Shi, F., Sun, G.-C., & Chen, H. (2013) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2013.08.008 · Cited by 189
Old drugs, novel ways out: Drug resistance toward cytotoxic chemotherapeutics
Wijdeven, R. H., Pang, B., Assaraf, Y. G., & Neefjes, J. (2016) · Drug Resistance Updates · doi:10.1016/j.drup.2016.07.001 · Cited by 187
Self-citationAPR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells
Mohell, N., Alfredsson, J., Fransson, Å., Uustalu, M., Byström, S., Gullbo, J., Hallberg, A., Bykov, V. J. N., Björklund, U., & Wiman, K. G. (2015) · Cell Death & Disease · doi:10.1038/cddis.2015.143 · Cited by 183
Corazao-Rozas, P., Guerreschi, P., Jendoubi, M., André, F., Jonneaux, A., Scalbert, C., Garçon, G., Malet-Martino, M., Balayssac, S., Rocchi, S., et al. (2013) · Oncotarget · doi:10.18632/oncotarget.1420 · Cited by 178
l-S,R-buthionine sulfoximine: historical development and clinical issues
Bailey, H. H. (1998) · Chemico-Biological Interactions · doi:10.1016/s0009-2797(97)00164-6 · Cited by 178
Glutathione peroxidase 4 (Gpx4) and ferroptosis: what's so special about it?
Conrad, M., & Friedmann Angeli, J. P. (2015) · Molecular & Cellular Oncology · doi:10.4161/23723556.2014.995047 · Cited by 176
Inhibitors of the PD-1 Pathway in Tumor Therapy
LaFleur, M. W., Muroyama, Y., Drake, C. G., & Sharpe, A. H. (2018) · The Journal of Immunology · doi:10.4049/jimmunol.1701044 · Cited by 175
Inhibition of glutathione synthesis reverses Bcl-2-mediated cisplatin resistance.
Rudin, C. M., Yang, Z., Schumaker, L. M., VanderWeele, D. J., Newkirk, K. A., Egorin, M. J., Zuhowski, E. G., & Cullen, K. J. (2003) · PubMed · Cited by 174
Tanito, M., Agbaga, M.-P., & Anderson, R. E. (2007) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2007.03.018 · Cited by 173
Chronic Oxidative Stress Increases Growth and Tumorigenic Potential of MCF-7 Breast Cancer Cells
Mahalingaiah, P. K. S., & Singh, K. P. (2014) · PLoS ONE · doi:10.1371/journal.pone.0087371 · Cited by 172
Weng, M.-S., Chang, J.-H., Hung, W.-Y., Yang, Y.-C., & Chien, M.-H. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0728-0 · Cited by 172
Peng, X., Zhang, M.-Q.-Z., Conserva, F., Hosny, G., Selivanova, G., Bykov, V. J. N., Arnér, E. S. J., & Wiman, K. G. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.417 · Cited by 170
Kim, S. K., Yang, J. W., Kim, M. R., Roh, S. H., Kim, H. G., Lee, K. Y., Jeong, H. G., & Kang, K. W. (2008) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2008.05.011 · Cited by 170
The Mitochondrial Complex(I)ty of Cancer
Urra, F. A., Muñoz, F., Lovy, A., & Cárdenas, C. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00118 · Cited by 169
Tyrosine kinase inhibitors as modulators of ABC transporter-mediated drug resistance
Shukla, S., Chen, Z.-S., & Ambudkar, S. V. (2012) · Drug Resistance Updates · doi:10.1016/j.drup.2012.01.005 · Cited by 168
Self-citationGlutathione depletion overcomes resistance to arsenic trioxide in arsenic-resistant cell lines
Davison, K., Côté, S., Mader, S., & Miller, W. H. (2003) · Leukemia · doi:10.1038/sj.leu.2402876 · Cited by 165
Cruciferous Vegetables, Isothiocyanates, and Bladder Cancer Prevention
Abbaoui, B., Lucas, C. R., Riedl, K. M., Clinton, S. K., & Mortazavi, A. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201800079 · Cited by 164
Classical Chemotherapy: Mechanisms, Toxicities and the Therapeutc Window
Malhotra, V., & Perry, M. C. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.199 · Cited by 163
Mutant p53 reactivation by small molecules makes its way to the clinic
Bykov, V. J. N., & Wiman, K. G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.04.017 · Cited by 162
The Keap1/Nrf2 pathway in health and disease: from the bench to the clinic
O’Connell, M. A., & Hayes, J. D. (2015) · Biochemical Society Transactions · doi:10.1042/bst20150069 · Cited by 162
Targeting mitochondrial complex I using BAY 87-2243 reduces melanoma tumor growth
Schöckel, L., Glasauer, A., Basit, F., Bitschar, K., Truong, H., Erdmann, G., Algire, C., Hägebarth, A., Willems, P. H., Kopitz, C., et al. (2015) · Cancer & Metabolism · doi:10.1186/s40170-015-0138-0 · Cited by 161
Unraveling the Truth About Antioxidants: ROS and disease: finding the right balance
Kawagishi, H., & Finkel, T. (2014) · Nature Medicine · doi:10.1038/nm.3625 · Cited by 158
Nrf2 Pathway Regulates Multidrug-Resistance-Associated Protein 1 in Small Cell Lung Cancer
Ji, L., Li, H., Gao, P., Shang, G., Zhang, D. D., Zhang, N., & Jiang, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063404 · Cited by 158
McCollum, A. K., TenEyck, C. J., Sauer, B. M., Toft, D. O., & Erlichman, C. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1629 · Cited by 157
Bin, L. U., Gong, X., Wang, Z., Ding, Y., Wang, C., Luo, T., Piao, M., Fan-kai, M. E. N. G., Chi, G., Luo, Y., et al. (2017) · Acta Pharmacologica Sinica · doi:10.1038/aps.2017.112 · Cited by 157
Wang, L., Yang, Z., Fu, J., Yin, H., Xiong, K., Tan, Q., Jin, H., Li, J., Wang, T., Tang, W.-C., et al. (2011) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2011.11.034 · Cited by 152
Giannoni, E., Fiaschi, T., Ramponi, G., & Chiarugi, P. (2009) · Oncogene · doi:10.1038/onc.2009.77 · Cited by 152
Cancer chemoresistance; biochemical and molecular aspects: a brief overview
Kachalaki, S., Ebrahimi, M., Khosroshahi, L. M., Mohammadinejad, S., & Baradaran, B. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.03.025 · Cited by 152
Raedler, L. A. (2015) · PubMed · Cited by 151
Polewski, M. D., Reveron‐Thornton, R. F., Cherryholmes, G. A., Marinov, G. K., Cassady, K. M., & Aboody, K. S. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0028 · Cited by 151
Protein oxidation an overview of metabolism of sulphur containing amino acid cysteine
Ahmad, S., Khan, H., Shahab, U., Rehman, S., Rafi, Z., Khan, M. Y., Ansari, A., Siddiqui, Z., Ashraf, J. M., Abdullah, S. M. S., et al. (2016) · Frontiers in Bioscience-Scholar · doi:10.2741/s474 · Cited by 148
Gào, X., & Schöttker, B. (2017) · Oncotarget · doi:10.18632/oncotarget.17128 · Cited by 147
The nox4 inhibitor gkt137831 attenuates hypoxia-induced pulmonary vascular cell proliferation
Green, D. E., Murphy, T. C., Kang, B.-Y., Kleinhenz, J. M., Szyndralewiez, C., Page, P., Sutliff, R. L., & Hart, C. M. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2011-0418oc · Cited by 146
Miyake, T., Nakayama, T., Naoi, Y., Yamamoto, N., Otani, Y., Kim, S. J., Shimazu, K., Shimomura, A., Maruyama, N., Tamaki, Y., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02231.x · Cited by 146
Cheng, C.-W., Kuo, C.-Y., Fan, C.-C., Fang, W.-C., Jiang, S. S., Yk, L., Wang, T.-Y., Kao, M.-C., & Lee, A. Y.-L. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.204 · Cited by 143
Mitochondrial Electron Transport Is the Cellular Target of the Oncology Drug Elesclomol
Blackman, R. K., Cheung-Ong, K., Gebbia, M., Proia, D. A., He, S., Kepros, J., Jonneaux, A., Marchetti, P., Kluza, J., Rao, P. E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0029798 · Cited by 141
Nrf2 is the key to chemotherapy resistance in MCF7 breast cancer cells under hypoxia
Syu, J.-P., Chi, J., & Kung, H. (2016) · Oncotarget · doi:10.18632/oncotarget.7406 · Cited by 141
Manganese superoxide dismutase promotes anoikis resistance and tumor metastasis
Kamarajugadda, S., Cai, Q., Chen, H., Nayak, S., Zhu, J., He, M., Jin, Y., Zhang, Y., Ai, L., Martin, S. S., et al. (2013) · Cell Death and Disease · doi:10.1038/cddis.2013.20 · Cited by 140
Weinstock, C., Khozin, S., Suzman, D. L., Zhang, L., Tang, S. W., Wahby, S., Goldberg, K. B., Kim, G., & Pazdur, R. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0540 · Cited by 139
Romidepsin for the treatment of cutaneous T-cell lymphoma
Campàs-Moya, C. (2009) · Drugs of today · doi:10.1358/dot.2009.45.11.1437052 · Cited by 138
Ju, H.-Q., Gocho, T., Aguilar, M., Wu, M., Zhuang, Z.-N., Fu, J., Yanaga, K., Huang, P., & Chiao, P. J. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0420 · Cited by 137
Ishii, T., & Mann, G. E. (2014) · Redox Biology · doi:10.1016/j.redox.2014.04.008 · Cited by 137
Dung, N. T., Kim, J. M., & Kang, S. C. (2008) · Food and Chemical Toxicology · doi:10.1016/j.fct.2008.09.013 · Cited by 136
Cited by
Biomedicine Meets Fenton Chemistry
Tang, Z., Zhao, P., Wang, H., Liu, Y., & Bu, W. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00977 · Cited by 745
CRISPR/Cas9 therapeutics: progress and prospects
Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P.-F., & Yu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01309-7 · Cited by 719
The interaction between ferroptosis and lipid metabolism in cancer
Li, D., & Li, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00216-5 · Cited by 703
Erin, N., Grahovac, J., Brozovic, A., & Efferth, T. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100715 · Cited by 527
NAD+ metabolism, stemness, the immune response, and cancer
Navas, L. E., & Carnero, A. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00354-w · Cited by 517
Metadata
- Authors
- Cui, Q., Wang, J.-Q., Assaraf, Y. G., Ren, L., Gupta, P., Wei, L., Ashby, C. R., Yang, D.-H., & Chen, Z.-S.
- Venue
- Drug Resistance Updates
- Publisher
- Elsevier BV
- Published
- 2018-11
- Volume
- 41
- Pages
- 1-25
- ISSN
- 1368-7646 (ISSN-L)
- OpenAlex
- W2901265038
- Cited by
- 661
- References
- 435
- FWCI
- 16.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.